(12) Patent Application Publication (10) Pub. No.: US 2012/0258972 A1 Rafi Et Al
Total Page:16
File Type:pdf, Size:1020Kb
US 20120258972A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0258972 A1 Rafi et al. (43) Pub. Date: Oct. 11, 2012 (54) COMPOSITION AND METHODS FOR A63/496 (2006.01) TREATING HARLOSS A6IP 7/4 (2006.01) (52) U.S. Cl. .................................... 514/254.07: 514/275 (76) Inventors: Asif Rafi, Los Angeles, CA (US); Roger M. Katz, Marina Del Rey, (57) ABSTRACT CA (US) A method for treatinghair loss caused by androgenicalopecia and/or male pattern baldness. The method, which not only (21) Appl. No.: 13/440,304 slows hair loss but causes hair re-growth, includes approxi mately daily application to a subject's Scalp of a novel com (22) Filed: Apr. 5, 2012 position comprising finasteride (PropeciaR) or Proscar(R), O O dutasteride (Avodart(R), and minoxidil (RogaineR) as active Related U.S. Application Data ingredients in a hypoallergenic cream-based vehicle, prefer (60) Provisional application No. 61/472,567, filed on Apr. ably coupled with daily ingestion of 1 mg per day of finas 6, 2011. teride (PropeciaR) or Proscar R), application to the scalp of 5% minoxidil (RogaineR) foam approximately once per day, O O and use of a ketoconazole-containing shampoo (e.g., Publication Classification Nizoral R) approximately 2-3 times per week. The method (51) Int. Cl. described herein also resolves Scalp dermatitis in atopic Sub A6 IK3I/506 (2006.01) jects Suffering therefrom. A method for making the novel A6IP3I/O (2006.01) composition is also provided. US 2012/0258.972 A1 Oct. 11, 2012 COMPOSITION AND METHODS FOR which causes the hair follicles to shrink. This is believed to TREATING HARLOSS shorten their lifespan and their anagen (growth) phase and prevent them from producing hair normally. CROSS-REFERENCE TO RELATED 0008 More specifically, hair growth begins under the skin APPLICATIONS in structures called follicles. Each strand of hair normally grows for approximately 2 to 6 years, goes into a resting phase 0001. This patent application claims the benefit of U.S. for several months, and then falls out. The cycle starts over Provisional Patent Application Ser. No. 61/472,567 filed Apr. when the follicle begins growing a new hair. Increased levels 6, 2011 for Method for Treating Hair Loss, which application of androgens, particularly dihydrotestosterone, in hair fol is incorporated in its entirety herein by this reference. licles can lead to a shorter cycle of hair growth and the growth of shorter and thinner strands of hair. Additionally, there is a BACKGROUND OF THE INVENTION delay in the growth of new hair to replace Strands that are 0002 1. Technical Field shed. 0003. This invention relates to novel methods and a novel 0009 Men with male pattern baldness typically have composition for treatment of hair loss by inducing hair higher levels of 5-alpha reductase, lower levels of total test growth in individuals Suffering from androgenic alopecia. osterone, higher levels of unbound/free testosterone, and 0004 More specifically, this invention relates to a novel higher levels of total free androgens including dihydrotest regimen for inducing hair growth through a treatment osterone. As noted above, 5-alpha reductase is known to have approach involving topical application of the composition to isoforms. Type I and Type II. Notably, men who have a described herein. Said treatment approach can be supple congenital deficiency of the Type II isozyme do not experi mented with additional steps, which may further induce hair ence male pattern baldness. growth and/or limit hair loss. Said treatment approach 0010 Males who have male pattern baldness typically depends, in part, on inhibition of one or both of the isozymes observe hair loss in a well-defined pattern, beginning above of the enzyme 5-alpha reductase, which converts testosterone both temples. Over time, the hairline recedes to form a char to dihydrotestosterone. Dihydrotestosterone is believed to be acteristic “M” shape. Hair also thins at the crown (near the top responsible for androgenic alopecia, or male pattern bald of the head), often progressing to partial or complete bald ness, in those who are genetically predisposed for Such a ness. The pattern of hair loss in women differs from male condition. pattern baldness. In women, the hair becomes thinner all over 0005 2. Background Art the head, but the hairline does not recede. Androgenic alope 0006 Androgenic alopecia, also called male pattern bald cia in women rarely leads to total baldness. ness, is a common phenomena, and is most commonly seen in 0011. At present, most treatment modalities for male pat men whose hair follicles are sensitive to dihydrotestosterone, tern baldness are not FDA approved and overall are not par which is the product of the testosterone-reducing enzyme ticularly effective. The high prevalence of male pattern bald 5-alpha reductase. Male pattern baldness affects approxi ness, the typically early age of onset, and the large degree of mately 30% of men by the age of 30, 50% of men by age 50, associated psychosocial symptoms have created a large mar and 57% of men by age 60. See, Melia J. M., Perret M. C., ket for treatment of male pattern baldness. Despite the para Manzotti M., Catalano H. N. Guyatt G. Efficacy and Safely mount demand for male pattern baldness treatment, there are of Finasteride Therapy for Androgenetic Alopecia, Archives only two FDA approved medications. However, they are of Dermatology (2010) 146(10): 1141-1150; Ellis J. A. Sin costly and may have side effects. clair R. Harrap S. B., Androgenetic Alopecia. Pathogenesis 0012. The two FDA approved medications used to treat and Potential for Therapy, Expert Rev. Mol. Med. (2002) male pattern baldness include topical minoxidil (Rogaine R; 4(22): 1-11: Norwood O. T., Hair Transplant Surgery, Johnson & Johnson) and finasteride (PropeciaR); Merck). Springfield, Ill. (Charles C. Thomas Publishers) 1973:3-16: Minoxidil is a vasodilator which is directly applied to the Rajput R.J., Controversy: Is There a Role for Adjuvants in the scalp to stimulate growth of the hair follicles. Topical minoxi Management of Male Pattern Hair Loss? Journal of Cutane dil slows hair loss for many men, while in Some men it grows ous and Aesthetic Surgery. (2010) 3(2): 82-86. Females can new hair. The previous degree of hair loss returns when solu also experience androgenic alopecia to Some degree, tion application is discontinued. Minoxidil is available in 2% although its manifestation in terms of the loci of hair loss is and 5% solutions, and a 5% foam version that became avail different than that observed in men. Olsen E. A., Hordinsky able in 2007. M., Whiting D., Stough D., Hobbs S., Ellis M., Wilson T., 0013 PropeciaR 1 mg (oral) was approved by the FDA in Rittmaster R. S., The Import ice of Dual 5 Alpha Reductase 1998 for androgenic alopecia. PropeciaR (finasteride), is a Inhibition in the Treatment of Male Pattern Hair Loss. Results prescription pill that inhibits the production of dihydrotest of a Randomized Placebo-Controlled Study of Dutasteride osterone (DHT), which is accomplished primarily by block Versus Finasteride, Journal of the American Academy of ing the activity of the Type II isoform of 5-alpha reductase. Dermatology (2006) 55(6): 1014-1023; Olsen E. Pattern Like minoxidil, finasteride is likely to slow hair loss, and may Hair Loss. In: Disorders of hair Growth. Diagnosis and also stimulate new hair growth. In general, finasteride is Treatment, New York: McGraw Hill (2003)321-362; Sinclair somewhat more effective than minoxidil, and it is more effec R., Male Pattern Androgenetic Alopecia, British Medical J. tive when combined with minoxidil. As with minoxidil, one's (1998)317: 865-869; Whiting D.A., Male Pattern Hair Loss: previous degree of hair loss returns when finasteride is dis Current Understanding, Int. J. Dermatol. (1998) (37): 561 continued. 566; Wilson J. D., Griffin J. E., Russell D. W., Steroid 5Alpha 0014. There are other medications available on the market Reductase 2 Deficiency, Endocr. Rev. (1993) (14): 577-593. that claim to treat male pattern baldness. These medications, 0007 Male pattern baldness is thought to be caused by a however, are not FDA approved for treating male pattern genetic sensitivity of hair follicles to dihydrotestosterone, baldness. Ketoconazole (NiZoral(R: Johnson & Johnson) US 2012/0258.972 A1 Oct. 11, 2012 shampoo, is known to inhibit 5-alpha reductase, Preliminary Kyon H. Young Sim W. Lynn Lew B. Lee W. S. Young Park research Suggests that ketoconazole shampoo may be benefi H., Phil Hong S., Hong Ji J. Efficacy, Safety, and Tolerability cial in men Suffering from androgenic alopecia. Downs M., of Dutasterie 0.5 mg Once Daily in Male Patients with Male Nizoral Shampoo/or Hair Loss, DERMAdoctor, www.der Pattern Hair LOSs. A Randomized, Double Blind, Placebo madoctor.com (2011); Piérard-Franchimont C., De Doncker Controlled, Phase III Study, Journal of the American Acad P. Cauwenbergh G. Piérard G. E., Ketoconazole Shampoo. emy of Dermatology (2010) 63(2): 252-258; Sato T., Sonoda Effect of Long-Term Use in Androgenic Alopecia, Dermatol T., Itami S. Takayasu S. Predominance of Tipe I 5 Alpha ogy (1998) 196(4): 474-477. Support for this also sterns from Reductase in Apocrine Sweat Glands of Patients With Exces a study in 1998 which compared ketoconazole shampoo 2% sive or Abnormal Odour Derived From Apocrine Sweat (os to the proven hair loss drug minoxidil in men with androgenic midrosis), Br. J. Dermatol. (1998) 139: 806-810: Thiboutot alopecia. Piérard-Franchimont C., De Doncker P. Cauwen D., Harris G., Iles V., Cimis G., Gilliland K. Hagari S., bergh G. Piérard G. E., Ketoconazole Shampoo. Effect of Activity of the Tipe I 5 Alpha-Reductase Exhibits Regional Long-Term Use in Androgenic Alopecia, Dermatology (1998) Differences in Isolated Sebaceous Glands and Whole Skin, J.